Literature DB >> 21942715

Proteomic dissection of the von Hippel-Lindau (VHL) interactome.

Yanlai Lai1, Meihua Song, Kevin Hakala, Susan T Weintraub, Yuzuru Shiio.   

Abstract

The von Hippel-Lindau (VHL) tumor suppressor gene encodes a component of a ubiquitin ligase complex containing elongin B, elongin C, cullin 2, and Rbx1, which acts as a negative regulator of hypoxia inducible factor (HIF). VHL ubiquitinates and degrades the alpha subunits of HIF, and this is proposed to suppress tumorigenesis and tumor angiogenesis. Several lines of evidence also suggest important roles for HIF-independent VHL functions in the maintenance of primary cilium, extracellular matrix formation, and tumor suppression. We undertook a series of proteomic analyses to gain a comprehensive picture of the VHL-interacting proteins. We found that the ARF tumor suppressor interacts with VHL30, a longer VHL isoform, but not with VHL19, a shorter VHL isoform. ARF was found to release VHL30 from the E3 ligase complex, promoting the binding of VHL30 to a protein arginine methyltransferase, PRMT3. Our analysis of the VHL19 interactome also uncovered that VHL19 displays an affinity to collagens and their biosynthesis enzymes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21942715      PMCID: PMC3208728          DOI: 10.1021/pr200642c

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  29 in total

Review 1.  The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.

Authors:  Robert E Barry; Wilhelm Krek
Journal:  Trends Mol Med       Date:  2004-09       Impact factor: 11.951

Review 2.  The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing.

Authors:  William G Kaelin
Journal:  Biochem Biophys Res Commun       Date:  2005-08-30       Impact factor: 3.575

Review 3.  Divorcing ARF and p53: an unsettled case.

Authors:  Charles J Sherr
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

Review 4.  Role of VHL gene mutation in human cancer.

Authors:  William Y Kim; William G Kaelin
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

5.  Ribosomal protein rpS2 is hypomethylated in PRMT3-deficient mice.

Authors:  Rafal Swiercz; Donghang Cheng; Daehoon Kim; Mark T Bedford
Journal:  J Biol Chem       Date:  2007-04-17       Impact factor: 5.157

6.  p53 stabilization and transactivation by a von Hippel-Lindau protein.

Authors:  Jae-Seok Roe; Hyungsoo Kim; Soon-Min Lee; Sung-Tae Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cell       Date:  2006-05-05       Impact factor: 17.970

7.  Ribosomal protein S2 is a substrate for mammalian PRMT3 (protein arginine methyltransferase 3).

Authors:  Rafal Swiercz; Maria D Person; Mark T Bedford
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

8.  pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.

Authors:  O Iliopoulos; M Ohh; W G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

9.  Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor.

Authors:  Alexandra Grosfeld; Ineke P Stolze; Matthew E Cockman; Christopher W Pugh; Mariola Edelmann; Benedikt Kessler; Alex N Bullock; Peter J Ratcliffe; Norma Masson
Journal:  J Biol Chem       Date:  2007-03-05       Impact factor: 5.157

10.  Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans.

Authors:  Tammie Bishop; Kah Weng Lau; Andrew C R Epstein; Stuart K Kim; Min Jiang; Delia O'Rourke; Christopher W Pugh; Jonathan M Gleadle; Martin S Taylor; Jonathan Hodgkin; Peter J Ratcliffe
Journal:  PLoS Biol       Date:  2004-09-07       Impact factor: 8.029

View more
  22 in total

Review 1.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

Review 2.  Protein arginine methyltransferases and cancer.

Authors:  Yanzhong Yang; Mark T Bedford
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

3.  Metastatic Renal Cell Cancer-Systemic Therapy.

Authors:  Amit Joshi; Arvind Sahu; Vanita Noronha; Vijay Patil; Kumar Prabhash
Journal:  Indian J Surg Oncol       Date:  2018-01-29

4.  Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors.

Authors:  Feng Liu; Fengling Li; Anqi Ma; Elena Dobrovetsky; Aiping Dong; Cen Gao; Ilia Korboukh; Jing Liu; David Smil; Peter J Brown; Stephen V Frye; Cheryl H Arrowsmith; Matthieu Schapira; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2013-02-27       Impact factor: 7.446

5.  The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF.

Authors:  Daniel Tarade; Shelley He; Jonathan St-Germain; Avi Petroff; Anya Murphy; Brian Raught; Michael Ohh
Journal:  Protein Sci       Date:  2020-06-25       Impact factor: 6.725

6.  A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6.

Authors:  Yudao Shen; Fengling Li; Magdalena M Szewczyk; Levon Halabelian; Irene Chau; Mohammad S Eram; Carlo Dela Seña; Kwang-Su Park; Fanye Meng; He Chen; Hong Zeng; Aiping Dong; Hong Wu; Viacheslav V Trush; David McLeod; Carlos A Zepeda-Velázquez; Robert M Campbell; Mary M Mader; Brian M Watson; Matthieu Schapira; Cheryl H Arrowsmith; Rima Al-Awar; Dalia Barsyte-Lovejoy; H Ümit Kaniskan; Peter J Brown; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2021-02-16       Impact factor: 7.446

7.  TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss.

Authors:  Lianxin Hu; Haibiao Xie; Xijuan Liu; Frances Potjewyd; Lindsey I James; Emily M Wilkerson; Laura E Herring; Ling Xie; Xian Chen; Johnny Castillo Cabrera; Kai Hong; Chengheng Liao; Xianming Tan; Albert S Baldwin; Kan Gong; Qing Zhang
Journal:  Cancer Discov       Date:  2019-12-06       Impact factor: 38.272

8.  The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2.

Authors:  P B Essers; T D Klasson; T C Pereboom; D A Mans; M Nicastro; K Boldt; R H Giles; A W MacInnes
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

9.  Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.

Authors:  Giovanni Minervini; Gabriella M Mazzotta; Alessandro Masiero; Elena Sartori; Samantha Corrà; Emilio Potenza; Rodolfo Costa; Silvio C E Tosatto
Journal:  Sci Rep       Date:  2015-07-27       Impact factor: 4.379

10.  Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2α expression.

Authors:  Lokesh Dalasanur Nagaprashantha; Tatjana Talamantes; Jyotsana Singhal; Jia Guo; Rit Vatsyayan; Navin Rauniyar; Sanjay Awasthi; Sharad S Singhal; Laszlo Prokai
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.